For example, the presented data of treatment with FGF-21 agonists or FGF-19 antibodies or analogues showed the great potential for their use in metabolic diseases, such as obesity, through beneficial effects on IS, lipid levels or food intake (Table 1). Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.